Short-Term Kinetics of Tumor Antigen Expression in Response to Vaccination
Open Access
- 1 August 2001
- journal article
- Published by The American Association of Immunologists in The Journal of Immunology
- Vol. 167 (3), 1809-1820
- https://doi.org/10.4049/jimmunol.167.3.1809
Abstract
The melanoma patient’s immune response to tumor has been extensively studied. Yet, the frequently observed coexistence of tumor-associated Ag (TAA)-specific T cells with their target cells in vivo remains unexplained. Loss of TAA expression might contribute to this paradox. We studied TAA expression in metastases by obtaining fine-needle aspirations from 52 tumor lesions in 30 patients with melanoma before and soon after immunotherapy. Limitations due to low amounts of starting material were overcome with a high fidelity antisense RNA amplification method. TAA expression was measured by quantitative real-time PCR of anti-sense RNA. Decrease in gp100/Pmel-17 TAA preceded tumor disappearance in several instances and could be best explained by immune selection because most patients had received gp100/Pmel-17-specific vaccination. Conversely, immune selection was absent in nonregressing lesions. These observations suggest that vaccination, when successful, triggers a broad inflammatory reaction that can lead to tumor destruction despite immune selection. Additionally, lack of clinical response might be attributed to lack of this initiating event rather than immune escape. This study provides an insight into the natural history of tumors and defines a strategy for the characterization of gene expression in tumors during therapy.Keywords
This publication has 35 references indexed in Scilit:
- Distinct types of diffuse large B-cell lymphoma identified by gene expression profilingNature, 2000
- Seeds of consensusNature, 2000
- MHC class I-restricted epitope spreading in the context of tumor rejection following vaccination with a single immunodominant CTL epitopeEuropean Journal of Immunology, 1999
- Immune selection after antigen-specific immunotherapy of melanomaSurgery, 1999
- Expression of immunotherapy candidate proteins GP100, Mart-1/Melan-A and tyrosinase in human melanocytic lesions and melanoma cell linesMelanoma Research, 1997
- Immunobiology of Human Melanoma Antigens MART-1 and gp100 and their Use for Immuno-Gene TherapyInternational Reviews of Immunology, 1997
- Expression of gp 100 in Melanoma Metastases Resected Before or After Treatment with IFN?? and IL-2Journal of Immunotherapy, 1996
- Analysis of Expression of the Melanoma-Associated Antigens MART-1 and gp lOO in Metastatic Melanoma Cell Lines and in In Situ LesionsJournal of Immunotherapy, 1996
- Structure, chromosomal localization, and expression of 12 genes of the MAGE familyImmunogenetics, 1994
- FINE SPECIFICITY AND IDIOTYPE DIVERSITY OF THE MURINE ANTI-HLA-A2, A28 MONOCLONAL ANTIBODIES CR11–351 AND KS1Transplantation, 1988